Conceptualizing and monetizing the full economic and social benefits of vaccines is currently the centerpiece of our life sciences practice.
Our analyses show that economists and policymakers have routinely failed to account for the full benefits of vaccine programs, suggesting that these programs have been substantially undervalued. The implication of this is that many decisions regarding vaccination adoption and scale-up, and investment in vaccine discovery and development, have not been well founded.
One key premise of our analyses is that vaccine costs are not properly judged as being high or low without reference to vaccine benefits. A second key premise is that the data analyses conducted to assess and compare vaccine costs and vaccine benefits must be customized to key features of epidemiological, economic, institutional, and country contexts, and to the nature and quality of the data at hand.
We are actively engaged in several pioneering efforts to value vaccines, based on these premises and faithful to well-established principles of finance and economics. We are also working to raise awareness about the appropriate use of benefit-cost and return-on- investment estimates in making rational policy decisions, regarding the inclusion of particular vaccines in national immunization programs and reimbursing their cost to end users.
Our efforts in the life sciences practice area are supported by a superlative team of health, labor, public finance, and development economists, econometricians and data scientists, and public health specialists.